1.. Introduction
================

Takayasu Arteritis (TA) is a chronic inflammatory condition with unclear etiology or pathology that mainly affects the aorta and its major branches, as well as pulmonary and coronary vessels, resulting in luminal stenosis and aneurismal dilation of large vessels^[@bib1])^. Once believed to be a rare disease affecting young women among Asian populations, the prevalence of TA has been established in both sexes, as well as ethnicities around the world^[@bib2],\ [@bib3])^.

Immunohistochemical studies of aortic tissues from patients with TA have demonstrated an infiltration of CD4+ T cells, CD8+ T cells, *γ δ* T cells, natural killer cells, macrophages, and neutrophils^[@bib4])^. Previous studies indicated that leukocytes could affect endothelial cells through leukocyte integrins and endothelial cell adhesion molecules of the immunoglobulin superfamily. Blocking leukocyte *α*4*β*1 or *α*4*β*7 integrins or their endothelial receptors mucosal addressin cell adhesion molecule 1 (MAdCAM-1) or vascular cell adhesion molecule 1 (VCAM-1) could prevent or reverse inflammation in various models^[@bib5])^. Vascular endothelial cell (EC) injury mediated by immunoreaction plays an essential role in the pathogenesis of TA. The involvement of apoptotic ECs in vascular lesions indicates that apoptosis may be one of the major pathways in inflammatory damage to ECs^[@bib6])^. What is more, the externalization of plasma membrane phosphatidylserine (PS) is a fundamental feature of apoptosis^[@bib7])^.

Ranging from 100 nm to 1 µm in diameter, microparticles (MPs) are small vesicles generated from membranes by the process of exocyte budding, resulting from either cell activation or apoptosis after a variety of stimuli. During the process of generating MPs, the plasma membrane PS transferred from inside layer to the out layer^[@bib8])^ with a tremendous increase in intracellular Ca^2+^ concentrations. The increase in the concentration of MPs under conditions of vascular injury or dysfunction reflects vascular health^[@bib9])^. Increased MPs from ECs (EMPs) and immune cells were found in inflammatory conditions, including rheumatoid arthritis (RA)^[@bib10])^, sepsis^[@bib11])^, systemic sclerosis^[@bib12])^, and systemic lupus erythematosus (SLE)^[@bib13])^.

Since endothelial dysfunction and inflammation are essential hallmarks of TA, we speculate that the concentrations of EMPs and MPs from immune cells might increase in the peripheral blood of patients with TA. To test this hypothesis, flow cytometry was used to analyze MPs isolated from patients with TA and healthy subjects, and the study determined the possible relationships between subpopulations of MPs and disease activity of TA.

2.. Materials and Methods
=========================

2.1. Patients and Healthy Subjects
----------------------------------

From December 2015 to June 2017, 32 consecutive, unselected patients with TA from our center were recruited for this study. All patients fulfilled the American College of Rheumatology criteria for TA^[@bib14])^, including at least 3 of the following criteria: 1) disease onset age ≤ 40 years, 2) claudication of extremities, 3) decreased brachial artery pressure, 4) a blood pressure difference between both arms ≥ 10 mmHg, 5) bruit over subclavian arteries or the aorta, and 6) abnormalities on arteriography. Patients with other connective tissue diseases, such as multiple sclerosis, RA, Behcet disease, ankylosing spondylitis, or rheumatic heart disease as comorbidities were excluded.

A patient with active TA was considered if two of the following criteria of the National Institutes of Health were presented new onset or worsening^[@bib15])^: 1) systemic signs or symptoms not attributable to other clinical conditions; 2) erythrocyte sedimentation rate (ESR) ≥ 20 mm/h and/or C-reactive protein (CRP) level ≥ 8 mg/l without infection or malignancy; 3) onset of signs or symptoms of vascular insufficiency; and 4) typical angiographic features.

Data on the clinical characteristics of all patients with TA were extracted from clinical medical records. After a rest of at least 5 minutes, blood pressure of each subject in a seated position was measured twice with a digital sphygmomanometer by a trained physician. The average value of these two measurements was used as the final blood pressure. A third measurement was not performed unless the difference between the first 2 measurements was more than 10 mmHg for systolic blood pressure. Hypertension was defined if the subject had a measured systolic blood pressure ≥ 140 mmHg, with or without diastolic blood pressure ≥ 90 mmHg, or if the patients were undergoing treatment for hypertension. Coronary heart disease was identified if the result of coronary angiography showed a reduction of more than 50% in the diameter of more than 1 major coronary artery^[@bib16])^. Two experienced interventional cardiologists reviewed the results of coronary angiography.

Healthy volunteers were recruited at our institute and comprised healthy check-up individuals. Subjects with hypertension, hyperlipidemia, or diabetes or subjects who were active smokers were excluded. The study complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Declaration of Helsinki and was approved by the ethics committee. All study subjects signed consent forms.

2.2. Laboratory Methods
-----------------------

Peripheral 12-h fasting venous blood samples were collected from subjects for the analysis of laboratory parameters and MPs. Laboratory exams were done within 2 hours of blood collection, and the parameters analyzed included white blood cell count, the counts and percentages of neutrophil granulocytes, lymphocytes, and monocytes, platelet (PLT), platelet crit (PCT) and levels of glucose (GLU), low-density lipoprotein cholesterol (LDL-C), high-sensitivity CRP (hs-CRP), ESR, and CRP. The level of CRP was detected with the Westergren method (Vacuette SRS100, Greiner Bio-One, Frickenhausen Germany). Hs-CRP and ESR levels were detected with immunoturbidimetry (Immage 800, Beckman Coulter Inc. Brea, USA). All analyses for different subjects were performed with the same instrument in the same clinical laboratory. The reference ranges for the counts and percentages of neutrophil granulocytes, lymphocytes, and monocytes were 1.8 × 10\^9/l-6.3 × 10\^9/l, 40%--75%, 1.1 × 10\^9/l-3.2 × 10\^9/l, 20.0%--50.0%, 0.10 × 10\^9/l-0.60 × 10\^9/l and 3.0%--10.0%, respectively.

2.2. Preparation of Platelet-free Plasma Samples
------------------------------------------------

As reported by the International Society of Extracellular Vesicles in 2013^[@bib17])^, samples for MP analysis were collected into EDTA-containing tubes, centrifuged (2,000 g for 10 minutes at 20 °C) within 2 hours to deplete blood cells, followed by another round of centrifugation (14,400 g for 10 minutes at 20°C) of the plasma to remove residual platelets making platelet-free plasma (PFP) and pelletizing MPs. All PFP samples were divided into 200-µl aliquots and stored at −80°C.

2.3. Labeling and Analysis of MPs by Flow Cytometry
---------------------------------------------------

To differentiate MPs from different origins, we used anti-human fluorescein isothiocyanate (FITC)-CD3 antibodies for T cells, anti-human phycoerythrin (PE)-CD19 antibodies for B cells and anti-human allophycocyanin (APC)-CD14 for monocytes. Considering the CD144 were indicated to be free of contaminating with a higher frequency^[@bib18])^, we used antihuman FITC-CD144 antibodies for ECs. At the same time, the PS on the surface of MPs was measured using PerCP-Cy5.5 Annexin (Anx)-V in the presence of ∼2.5 mM Ca^2+^.

PFPs for MP analysis were thawed and resuspended. All liquid reagents used were filtered through 0.2-µm pores (Pall Co., Ltd, USA) to decrease background signals. Then, 60 µl of each sample was divided into two equal parts. Each part was labeled with either 2.5 µl FITC-conjugated-anti-CD144 or a mix of 10 µl FITC-conjugated-anti-CD3, 10 µl PE-conjugated-anti-CD19 and 10 µl APC- conjugatedanti-CD14 antibodies at 4°C in the dark for 20 minutes. After labeling, samples were centrifuged with phosphate buffered saline (PBS) (20,000 g for 30 minutes at 4°C) to remove unbound antibodies. After that, each sample was mixed with 1 µl PerCP-Cy5.5-conjugated-AnxV and 50 µl binding buffer (2X) to detect whether the MPs were PS positive or not, followed by another labeling in the dark (20 minutes at 4°C). Unbound antibodies were removed with PBS as described above. Samples stained with isotype-matched non-specific antibodies (FITC-conjugated IgG1 kappa, PE-conjugated IgG1 kappa and APC-conjugated IgG1 kappa at the same concentration as the respective cell-marker antibodies) incubated under the same conditions were used as controls.

Beads at 1-µm diameter were used to mark the upper limit of MPs^[@bib19])^. Each sample was mixed with 50 µl (concentration at 500 beads/"l) 500-nm counting beads and 500 µl binding buffer (1X), followed by resuspension. The beads were then counted by a flow cytometer within an hour with a "high" flow-rate mode Becton Dickinson (BD Co., Ltd, USA) Influx cell sorter, which was under the control of BD FACS software version 1.2.0.137. Analysis was stopped once 2,000 beads had been counted. Absolute MP counts per milliliter of plasma were then calculated. The formula for the calculation of MP concentration was as follows: *C = N* × *(x/y)/30*, where *C* = total concentration of MPs; *N* = number of MPs counted; *x* = total number beads added (50 × number of beads per µl); *y* = number of beads counted (2,000); and 30 is the dilution factor. The concentration of each MP subpopulation was calculated by multiplying the concentration of total MPs by the proportion of total MPs. The flow rate was measured before each experiment. Both forward scatter (FSC) and side scatter (SSC) signals were recorded with logarithmic gain.

2.4. Statistical Analysis
-------------------------

Continuous data were presented as either the mean ± standard deviation or the median with interquartile range (IQR) depending on if data were normally distributed or not. Normality of continuous variables was assessed with Shapiro-Wilk tests. Two-tailed unpaired Student\'s t tests and the Mann--Whitney *U* test were used to compare the difference between two groups. Qualitative data were presented as number of subjects with percentages. Frequencies between groups were compared using chi-square test and Fisher\'s exact test.

Bivariate logistic regression analysis was used to assess the association between the concentrations of MP subpopulations and disease activity. The sensitivities and specificities were determined using receiver operating characteristic (ROC) curves. The Spearman approach was used to assess the associations between log-transformed MP subpopulation concentrations and other continuous variables, and *P* \< 0.1 was considered statistically significant. Multiple linear regression was performed to analyze the independence of correlations with variables and MP subpopulation concentrations.

Scatter plots were used with median presented by lines. *P* \< 0.05 was considered statistically significant. GraphPad Prism version 7.0 (GraphPad Software, La Jolla California USA) and SPSS version 25.0 (SPSS Inc., Chicago, IL, USA) were used for plotting and statistical analysis.

3.. Results
===========

3.1. Study Subjects
-------------------

A cohort of 51 subjects were included in this study; among them, 32 were patients with TA, with a median age of 49.5 years, while the other 19 subjects were healthy controls, with a median age of 35.0 years (*P* = 0.103). The proportion of males among patients with TA and healthy controls was 6.3% (2 in 32) and 21.1% (4 in 19), respectively (*P* = 0.179).

There were 18 patients in the active phase with 1 male (7.5%) included. And the age of patients with active TA was 43.1 ± 12.6y, similar to that of patients in remission phase (49.5 ± 14.1y, *P* = 0.182). The baseline data of blood cell proportions and concentrations were balanced between the patients with different phases of TA, as well as the data on treatment with statins and prednisone (**[Table 1](#T1){ref-type="table"}**).

###### Characteristics of patients with TA in remission and active phases

                    Group[§](#tf1){ref-type="table-fn"}                       
  ----------------- ------------------------------------- ------------------- ----------
  Male, %           1 (7.1)                               1 (5.6)             1.000
  Age, y            49.5 ± 14.1                           43.1 ± 12.6         0.182
  WBC, 10\^9/l      8.0 (7.3, 10.4)                       8.0 (6.3, 11.1)     0.694
  N, %              66 ± 8                                62 ± 8              0.207
  NC, 10\^9/l       5.4 (4.2, 6.8)                        4.5 (3.9, 6.5)      0.419
  L, %              27 ± 7                                30 ± 8              0.241
  LC, 10\^9/l       2.3 ± 0.7                             2.6 ± 1.1           0.334
  M, %              5.2 (4.5, 7.1)                        5.6 (5.1, 6.0)      0.561
  MC, 10\^9/l       0.5 (0.3, 0.6)                        0.4 (0.4, 0.7)      0.985
  PLT, 10\^9/l      216 (169, 254)                        259 (215, 360)      0.037
  PCT, %            0.23 (0.20, 0.27)                     0.26 (0.22, 0.35)   0.045
  GLU, mmol/l       4.8 (4.6, 5.7)                        4.4 (4.2, 5.0)      0.054
  LDL-C, mmol/l     2.3 ± 0.7                             2.3 ± 0.7           0.689
  hs-CRP, mg/l      1.9 (0.9, 10.6)                       5.5 (0.7, 11.3)     0.837
  ESR, mm/h         7.0 (4.8, 15.0)                       24.5 (11.5, 35.3)   \< 0.001
  CRP, mg/l         2.6 (1.5, 7.0)                        8.5 (2.3, 14.1)     0.037
  Hypertension, %   7 (50)                                4 (22.2)            0.142
  CHD, %            3 (21.4)                              9 (50.0)            0.147
  Prednisone, %     10 (71.4)                             13 (72.2)           1.000
  Statins, %        10 (71.4)                             10 (55.6)           0.471

Data are expressed as the median (IQR) or the mean (SD), unless otherwise indicated.

WBC, white blood cell; N, neutrophil percentage; NC, count of neutrophil; L, lymphocyte percentage; LC, count of lymphocyte; M, monocyte percentage; MC, count of monocyte; platelet volume distribution width; PLT, platelet; PCT, platelet crit; GLU, glucose; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; CHD, coronary heart disease.

*P* \< 0.05

3.2. Laboratory Findings
------------------------

The levels of ESR (24.5 vs. 7.0, *P* \< 0.001), CRP (8.5 vs. 2.6, *P* = 0.037), PLT (259 vs. 216, *P* = 0.037), and PCT (0.26 vs. 0.23, *P* = 0.045) were increased significantly in active TA patients compared with remission ones. No significant differences were observed regarding the distribution of various subpopulations of WBCs or levels of blood GLU or lipid between the two groups of patients with TA in remission and active phases.

3.3. Concentrations of MP Subpopulations in Different Groups
------------------------------------------------------------

Concentrations of total EMPs (54 × 10^3^ MPs /ml vs. 32 × 10^3^ MPs /ml, *P* = 0.0004), AnxV+ EMPs (22 × 10^3^ MPs /ml vs. 12 × 10^3^ MPs /ml, *P* = 0.0006), and AnxV− EMPs (31 × 10^3^ MPs /ml vs. 19 × 10^3^ MPs /ml, *P* = 0.0005) were significantly higher in patients with TA than in healthy controls (**[Fig. 1](#F1){ref-type="fig"}**).

![Comparisons of EMP subpopulations between healthy controls and patients with TA\
Concentrations of total EMPs ([Fig. 1A](#F1){ref-type="fig"}), AnxV+ ([Fig. 1B](#F1){ref-type="fig"}) and AnxV− EMPs ([Fig. 1C](#F1){ref-type="fig"}) were significantly increased in TA patients (A) than in healthy controls (C), with *P* values of 0.0004, 0.0006 and 0.0005, respectively. *P* \< 0.05](jat-26-547-g001){#F1}

Additionally, concentrations of total EMPs (85 × 10^3^ MPs /ml vs. 45 × 10^3^ MPs /ml, *P* = 0.016), AnxV + EMPs (39 × 10^3^ MPs /ml vs. 14 × 10^3^ MPs /ml, *P* = 0.0092) and AnxV− EMPs (47 × 10^3^ MPs /ml vs. 29 × 10^3^ MPs /ml, *P* = 0.0371) in patients with active TA were significantly increased than in remission ones (**[Fig. 2](#F2){ref-type="fig"}**).

![Comparisons of EMP concentrations between patients with TA in different phases\
Concentrations of total EMPs ([Fig. 2A](#F2){ref-type="fig"}), AnxV+ ([Fig. 2B](#F2){ref-type="fig"}) and AnxV− EMPs ([Fig. 2C](#F2){ref-type="fig"}) were significantly higher in patients with TA in active phase (A) than remission ones (R) with *P* values of 0.016, 0.0092 and 0.0371, respectively. *P* \< 0.05](jat-26-547-g002){#F2}

No significant difference was observed regarding concentrations of MPs from T cells, B cells or monocytes neither between healthy controls and patients with TA (**[Table 2](#T2){ref-type="table"}**) nor patients with different phases of TA (**[Table 3](#T3){ref-type="table"}**).

###### Comparison of TMP, BMP, and MMP concentrations in controls and patients with TA

  Variables, MPs (\*10^3^)/ml   Group[§](#tf3){ref-type="table-fn"}                    
  ----------------------------- ------------------------------------- ---------------- -------
  CD3 + MPs                     87 (67, 200)                          89 (53, 140)     0.965
  AnxV + CD3 + MPs              21 (14, 34)                           17 (13, 33)      0.828
  AnxV− CD3 + MPs               72 (48, 166)                          74 (52, 121)     0.836
  CD19 + MPs                    73 (54, 121)                          86 (60, 114)     0.736
  AnxV + CD19 + MPs             14 (9, 19)                            13 (8, 21)       0.996
  AnxV− CD19 + MPs              63 (44, 101)                          73 (53, 89)      0.754
  CD14 + MPs                    229 (110, 514)                        234 (131, 420)   0.810
  AnxV + CD14 + MPs             25 (17, 44)                           29 (11, 46)      0.791
  AnxV− CD14 + MPs              205 (89, 426)                         29 (101, 333)    0.530

Data are expressed as the median (IQR).

MPs, microparticles; TMP, T cell microparticles; BMP, B cell microparticles; MMP, monocytes microparticles; TA, Takayasu arteritis.

*P* \< 0.05

###### Comparison of TMP, BMP, and MMP concentrations in patients with different phases of TA

  Variables, MPs (\*10^3^)/ml   Group[§](#tf5){ref-type="table-fn"}                    
  ----------------------------- ------------------------------------- ---------------- -------
  CD3 + MPs                     89 (42, 143)                          88 (68, 153)     0.808
  AnxV + CD3 + MPs              19 (12, 34)                           16 (13, 32)      0.874
  AnxV− CD3 + MPs               76 (30, 124)                          73 (54, 121)     0.772
  CD19 + MPs                    78 (55, 110)                          97 (66, 119)     0.536
  AnxV + CD19 + MPs             14 (8, 22)                            13 (8, 22)       0.567
  AnxV− CD19 + MPs              64 (43, 85)                           81 (54, 109)     0.512
  CD14 + MPs                    223 (61, 386)                         240 (143, 553)   0.722
  AnxV + CD14 + MPs             29 (14, 45)                           29 (10, 54)      0.632
  AnxV− CD14 + MPs              192 (47, 319)                         193 (124, 397)   0.955

Data are expressed as the median (IQR).

MPs, microparticles; TMP, T cell microparticles; BMP, B cell microparticles; MMP, monocytes microparticles; TA, Takayasu arteritis.

*P* \< 0.05

There were four patients in this cohort experienced disease relapse. The concentrations of total EMPs, AnxV+ EMPs, and AnvV− EMPs were all increased (**[Table 4](#T4){ref-type="table"}**).

###### Concentrations of EMPs before and after relapse

  -----------------------------------------------------------------------------------------------------------
       ESR\     CRP\     Total EMPs\        AnxV+EMPs\         AnxV−EMPs\                               
       (mm/h)   (mg/l)   (× 10^3^ MPs/ml)   (× 10^3^ MPs/ml)   (× 10^3^ MPs/ml)                         
  ---- -------- -------- ------------------ ------------------ ------------------ ----- ---- ----- ---- -----
  1    7        23       10.8               34.5               17                 73    14   26    3    47

  2    12       65       1.13               10                 62                 341   12   225   50   117

  12   7        20       8.92               15.5               27                 88    10   38    18   51

  14   4        30       1.46               17.7               29                 149   10   46    20   103
  -----------------------------------------------------------------------------------------------------------

ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; MPs, microparticles; ErMPs, erythrocyte microparticles.

3.4. Relationships between Subpopulations of EMP and TA Activity
----------------------------------------------------------------

Single-factor bivariate logistic regression analysis indicated that concentrations of total EMPs (odds ratio \[OR\] = 1.024, 95% confidence interval \[CI\]: 1.001 to 1.048, *P* = 0.037), AnxV + EMPs (OR = 1.089, 95%CI: 1.011 to 1.172, *P* = 0.024) and AnxV− EMPs (OR = 1.029, 95% CI: 1.002 to 1.056, *P* = 0.034) were positively associated with disease activity. Areas under the curve (AUCs) for the concentrations of total EMPs, AnxV+ EMPs and AnxV− EMPs were 0.788 (95%CI: 0.63 to 0.947, *P* = 0.006), 0.794 (95% CI: 0.63 to 0.958, *P* = 0.005), and 0.761 (95% CI: 0.594 to 0.927, *P* = 0.012), respectively.

3.5. Concentrations of EMPs with Inflammatory Markers of TA
-----------------------------------------------------------

With Spearman approach, age, PLT and PCT were correlated with concentrations of total EMPs and AnxV− EMPs. PLT, PCT, and ESR were correlated with AnxV+ EMPs. With multiple linear regression analysis, PLT was correlated with concentrations of total EMPs (Standardized B= 0.419, *P* = 0.016) and AnxV− EMPs (Standardized B = 0.514, *P* = 0.003) independent of age, gender, PCT, ESR, hs-CRP, and CRP. And ESR was correlated with AnxV + EMPs (Standardized B = 0.474, *P* = 0.006) independent of age, gender, PLT, PCT, hs-CRP, and CRP (**[Table 5](#T5){ref-type="table"}**).

###### Independent predictors of EMPs by multiple linear regression analysis

                ρ        *P*[\*](#tf9){ref-type="table-fn"}   Standardized *β*   *P*[\*](#tf9){ref-type="table-fn"}
  ------------- -------- ------------------------------------ ------------------ ------------------------------------
  Total EMPs                                                                     
      age       −0.298   0.098                                                   
      gender    −0.028   0.879                                                   
      PLT       0.499    0.004                                0.419              0.016
      PCT       0.454    0.009                                                   
      ESR       0.292    0.105                                                   
      hs-CRP    −0.110   0.548                                                   
      CRP       0.006    0.975                                                   
  AnxV + EMPs                                                                    
      age       −0.209   0.250                                                   
      gender    −0.042   0.820                                                   
      PLT       0.345    0.053                                                   
  PCT           0.329    0.066                                                   
      ESR       0.337    0.059                                0.474              0.006
      hs-CRP    −0.061   0.741                                                   
      CRP       0.166    0.365                                                   
  AnxV− EMPs                                                                     
      age       −0.305   0.089                                                   
      gender    −0.056   0.761                                                   
      PLT       0.514    0.003                                0.514              0.003
      PCT       0.426    0.015                                                   
      ESR       0.155    0.396                                                   
      hs-CRP    −0.076   0.680                                                   
      CRP       −0.112   0.542                                                   

MPs, microparticles; EMPs, endothelial microparticles; AnxV, annexin V; PLT, platelet; PCT, platelet crit; ESR, erythrocyte sedimentation rate; hs-CRP, high sensitive C reactive protein; CRP, C reactive protein.

*P* \< 0.05

4.. Discussion
==============

To the best of our knowledge, this is the first study on MPs from ECs and WBC, including T cells, B cells and monocytes from patients with TA. The results indicated that the concentrations of EMPs, including total EMPs, AnxV + EMPs, and AnxV− EMPs were increased significantly in patients with TA, especially in patients with active TA. The concentrations of total EMPs, AnxV + EMPs, and AnxV− EMPs were associated positively with TA activity.

The concentration of total EMP was significantly increased in patients with TA than healthy subjects in this study. EMP is one of the most studied subpopulations of MPs, which released either from apoptotic ECs or ECs activated by a variety of triggers such as cytokines and complement activation. EMPs have been demonstrated to increase in various cardiovascular diseases, like CHD^[@bib20])^, pulmonary hypertension^[@bib21])^, diabetes, and rheumatic diseases such as RA^[@bib10])^, SLE^[@bib13])^, and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides in adults^[@bib22])^. The concentrations of total MPs and EMPs were demonstrated to be higher in patients with RA than in healthy controls. In atherosclerosis disease, EMPs release after the stimulations of oxidative stress, endogenous molecules, and apoptosis inducer leading to vascular dysfunction^[@bib23])^. However, as the pathology of atherosclerosis disease and TA are different, how EMPs are generated in TA is still unclear, which need further studies in the future. In this present study, we\'ve noticed that the EMP concentration in remission TA patients and healthy controls were similar, thus the significant difference between TA patients and healthy subjects on EMP levels should related to the high level of EMP in active TA patients. In addition, EMP concentrations in patients with other vasculitis were increased as well. With these considerations, the use of EMP in TA diagnosis might be limited.

The present study indicated that EMPs were positively related with TA activity and the concentrations of EMPs were increased when disease relapsed in four patients. A previous study reported that EMPs are related to disease specific features, including disease activity^[@bib10])^. In SLE, rather than anti-EC antibodies, EMPs released from the activated and apoptotic cells are the main cause of endothelial dysfunction^[@bib24])^. Assessed by flow-mediated dilatation (FMD), the levels of EMPs in patients with active SLE were significantly related to their vascular endothelium dysfunction. When the inflammation was suppressed, the absolute number of EMPs decreased with endothelial dysfunction of patients with SLE improved. In Kawasaki Disease, a kind of pediatric vasculitis, the concentrations of EMPs in the blood of patients were significantly higher than those in the blood of healthy controls and were negatively correlated with the values of FMD^[@bib25])^. After anti-inflammation treatment of patients with Henoch-Schonlein Purpura^[@bib26])^ and ANCA-associated vasculitis^[@bib27])^, the concentrations of EMPs were observed to significantly decrease^[@bib26])^, and the decrease in the concentrations of EMPs was much faster than EC numbers after disease remission^[@bib27])^. Thus, EMP could be considered as a measure to assess disease activity.

Blood MPs are derived from various vascular cells, such as monocytes, granulocytes, platelets, T cells, B cells, ECs and erythrocytes. In resting cells, plasma membranes are composed of two leaflets. The outer leaflet contains phosphatidylcholine and sphingomyelin, whereas the inner leaflet is rich in PS and phosphatidylethanolamine. The transbilayer lipid distribution occurs mainly under the conditions of significant and sustained increase of cytosolic Ca^2+^, which leads to the surface exposure of PS and release of MPs. Additionally, MPs may be released because of the mechanical destruction of cells or the loss of membrane integrity in necrotic cells^[@bib8])^. Considering the fact that not all MPs expose PS on their surface^[@bib28],\ [@bib29])^ and PS usually binds to AnxV, the study analyzed AnxV + and AnxV− MPs and indicated that independent of PS exposure, EMPs were positively correlated with TA activity.

There are several possible pathogenic effects of EMPs, notably on inflammation. In a model of human umbilical vein ECs (HUVECs), after treatment with TNF-*α*, EMPs were induced in a time-dependent manner, under the regulation of TNF receptor-1 or nuclear factor-*κ*B. By expressing proapoptotic molecules and increasing intercellular adhesion molecule-1, EMPs promote monocyte adhesion and contribute to inflammation in ECs^[@bib30])^. Some EMPs contains apoptosis-modified chromatin and upregulates the levels of co-stimulatory surface molecules and pro-inflammatory cytokines such as IL-6, TNF-*α* and IFN-*α*, and initiate NETosis in blood-derived neutrophils^[@bib31])^. Certolizumab, a TNF-*α* inhibitor, could prevent the production of EMPs by activated ECs indicating a new mechanism of anti-TNF therapy and suggested that EMPs could be an important therapeutic target^[@bib32])^. EMPs also play a role in hemostasis and thrombosis^[@bib33])^. This is largely related to the exposure of PS and tissue factor (TF). Based on control studies with EMPs from anti-human TF antibodytreated and non-activated HUVECs, EMPs from activated ECs expose TF on their surface, which is responsible for coagulant activity both *in vivo* and *in vitro*^[@bib34])^. The role of EMPs in endothelium function is controversial. In the report by Brodsky^[@bib35])^, EMPs were shown to impair vasorelaxation and nitric oxide production by aortic ring cells in a concentration-dependent manner in Sprague--Dawley rats. In mice, vitro experiments indicated that EMPs promote EC migration and proliferation by delivering miR-126 and further regulating the expression of the target protein SPRED1^[@bib36])^. However, one study reported that EMPs released by cultured cells inhibit angiogenesis in mouse models of atherosclerosis^[@bib37])^. In addition, in clinical studies, EMPs were shown to protect vessels under conditions of acute vascular stress, like septic shock^[@bib38])^. The effects of EMPs on vessels are likely dependent on the particular stimuli or the microenvironment^[@bib39])^. Instead of being a functionless marker of injury, EMPs might thus be a pivotal factor delivering downstream pro-inflammatory factors that can protect vessels from acute vascular inflammation and maintain, or even ameliorate vascular dysfunction in chronic diseases^[@bib40])^.

In contrast with some previous MP studies in immunological diseases^[@bib12],\ [@bib41])^, the concentrations of MPs from lymphocytes and monocytes in patients with TA were similar to those in healthy controls in this present study. These observations may be related to the long-term disease course in these patients, as lymphocytes play a role in disease pathogenesis during the early stages of disease, whereas ECs come into play in late stages. Secondly, lymphocytes and monocytes were mainly observed within erosional vessel walls, thus, it is possible that lymphocytes and monocytes may affect in TA pathophysiology at sites of inflammation, while ECs play a role via releasing MPs in peripheral blood. Last but not the least, a previous study proved that in the peripheral blood from active TA patients, the ratio of CD4+/CD8+ T cells^[@bib42])^ and HLA-DR circulating T cells^[@bib43])^ were increased. This present study only calculated CD3+ MPs from T cells, but MPs from different subpopulations of T cells or the ratios of them were not considered.

There are several limitations need to be considered in this study. First, the current study is cross-sectional and makes it difficult to make out a causal relationship between MPs and TA. Second, despite of the fact that there are no criteria for EMPs detecting, and previous studies indicated that CD144 positive EMPs were increased in other vasculitis and proved to be free of contaminating with a higher frequency than others^[@bib44])^. The study only examined CD144+ EMPs, which represent one subpopulation of EMPs, while other populations like CD62E+ and CD31 + EMPs were not included in this study. This is the same issue when examining MPs from T cells, B cells and monocytes, for which the study only considered CD3+, CD19+ and CD14+ subpopulations, respectively. More studies on MPs from subpopulations of different parental cells, and functions of EMPs in patients with TA and the mechanisms by which the EMPs participate in TA pathophysiology are warranted both *in vivo* and *in vitro*. Third, some studies indicated antinuclear antibodies (ANA), IgG^[@bib45])^, IL-6 and TNF-*α* increased in TA patients, though the results were controversial and uncertain ^[@bib46]--[@bib14])^. The relationships between these potential markers with MPs were not included in this study and could be analyzed in the following research. Last, as intergrins and adhesion molecules play essential roles in leukocytes and ECs interaction, MPs might be related to these molecules in pathology. Further studies on this issue could be considered in the future.

Conclusion
==========

Concentrations of endothelial microparticles are increased significantly in active Takayasu arteritis patients comparing with remission ones and correlated positively with inflammation in Takayasu arteritis. EMPs could be useful markers in assessing disease activity.
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